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BRIEF COMMUNICATION
The impact of COVID-19 on systemic anticancer treatment
delivery in Scotland
Mark A. Baxter 1,2, John Murphy3, David Cameron4,5, Judith Jordan6, Christine Crearie7, Christina Lilley5, Azmat Sadozye7,
Mary Maclean7, Peter Hall 4,5, Angela Phillips2, Alex Greger6, Jude Madeleine8 and Russell D. Petty 1,2
Understanding the impact of the COVID-19 pandemic on systemic anticancer therapy delivery (SACT) is crucial to appreciate the
short- and long-term consequences for cancer patients and plan future care. Here, we report real-time national SACT delivery data
from NHS Scotland. We demonstrate an initial rapid reduction in patient attendance of 28.7% with subsequent rapid recovery
following service redesign. The smallest decrease was seen in breast cancer (19.7%), which also had the most rapid recovery and
the largest decrease seen in colorectal cancer (43.4%). Regional variation in the magnitude of impact on SACT delivery was
observed, but nadirs occurred at the same time and the rate of recovery was similar across all regions. This recovery reflected a
coordinated national approach and associated patient and clinician support structures, which facilitated the creation of COVID-19-
protected areas for SACT delivery in Scottish cancer centres enabling rapid sharing of successful and innovative strategies. The data
show that these actions have limited the disadvantage to cancer patients.
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BACKGROUND
COVID-19 (SARS-CoV-2) has impacted significantly on the delivery
of cancer care, including systemic anticancer therapy (SACT), in
the United Kingdom (UK). During the pandemic major reductions
in cancer screening, diagnostic tests or treatment have been
observed.1
Early studies suggested that cancer patients were at increased
risk of SARS-CoV-2 infection and that SACT was associated with
severe COVID-19 outcomes.2 In addition, the delivery of SACT
while maintaining social distancing is challenging. Patient
attendance for treatment increases the risk of transmission of
infection for both patients and staff. These factors led to
uncertainty for cancer clinicians.3
In response, the National Institute of Clinical Excellence (NICE)
produced a guideline regarding the delivery of SACT for England,
while in Scotland, the Scottish Government introduced interim
governance arrangements for cancer medicines.4,5
UK cancer units adapted and clinicians consulted with patients
regarding the potential risk of continuing treatment. Focus turned
to immunosuppressive regimes and immune checkpoint inhibitors
due to the risk of neutropenia and cytokine storm, respectively.6
Ultimately, these adaptations led to a reduction in delivery of
SACT. In England and Northern Ireland, data suggested that
patient attendances for SACT reduced initially by 45–66%.7
The need for evidence to guide decisions led to the
development of prospective observational studies such as the
UK Coronavirus Cancer Monitoring Project (UKCCMP).8 UKCCMP
has rapidly collected data with weekly reports provided to 96
participating centres.
The UKCCMP alongside the US COVID-19 and Cancer Con-
sortium (CCC19)9 have recently demonstrated that outcomes in
cancer patients with COVID-19 are largely driven by age, gender
and comorbidity. No detrimental effect of SACT was observed on
patient outcomes. These new data provide welcome reassurance
that SACT including chemotherapy should be offered to patients if
possible. However, these studies had short follow-up time and
their retrospective nature led to high proportions of missing data
and incomplete adjustment for confounders, and consequently
many unanswered questions.10
Knowledge of the extent of the impact COVID-19 has on cancer
treatment delivery is important for future planning, and to
minimise disadvantage to patients in the event of a resurgence
of infection. In this rapid short report, we present real-time
nationwide data from Scotland on cancer patient attendance for
SACT during the COVID-19 pandemic. We demonstrate the impact
on a regional and national level and discuss reasons for patterns
seen and conclusions for future SACT delivery during the ongoing
COVID-19 pandemic.
METHODS
Cancer care in NHS Scotland is delivered across 14 geographic
health boards and coordinated by three Regional networks: North
of Scotland Cancer Alliance (NCA, population 1,396,780), West of
Scotland Cancer Network (WoSCAN, population 3,158,940) and
South East Cancer Network (SCAN, population 1,509,500). In all
Health boards, SACT is prescribed using the same electronic
prescribing system, ChemoCare® (CIS Oncology Ltd, Belfast, UK).
www.nature.com/bjc
Received: 11 August 2020 Revised: 6 January 2021 Accepted: 7 January 2021
1Division of Molecular and Clinical Medicine, Ninewells Hospital and Medical School, University of Dundee, Dundee, UK; 2Tayside Cancer Centre, Ninewells Hospital and Medical
School, NHS Tayside, Dundee, UK; 3NHS Lanarkshire, South Lanarkshire, UK; 4Edinburgh Cancer Research Centre, University of Edinburgh, Edinburgh, UK; 5Edinburgh Cancer
Centre, NHS Lothian, Edinburgh, UK; 6NHS Grampian, Aberdeen, UK; 7West of Scotland Cancer Network, Glasgow, UK and 8NHS Highland, Inverness, UK
Correspondence: Russell D. Petty (r.petty@dundee.ac.uk)
© The Author(s) 2021, corrected publication 2021
This enables data on the number of patients attending for SACT to
be extracted rapidly and in real time.
Following the UK-wide lockdown on 23 March 2020, SACT
patient attendance and treatment episode (a single SACT
administration, reflecting the instances where a patient may
attend once but receive more than one treatment such as
intravenous (IV) and oral (PO) SACT) numbers were collated weekly
from each health board and grouped by the responsible regional
Cancer Network, for discussion and review at the national level.
Patient attendance for 6 weeks or treatment episodes for 8 weeks
prior to lockdown were collected for comparison. The χ2 test was
used to compare differences in patient attendances or treatment
episodes. A two-sided p value of <0.05 denoted statistical
significance. All statistical analyses were done using GraphPad
Prism (version 6.0).
PREPRINT
A previous version of this manuscript was published as a preprint
[27 August 2020].
RESULTS
Adult patient attendances for SACT in NHS Scotland showed a
sudden decrease that was not seen in previous years, in the
week preceding the UK lockdown. This decrease continued until
the week beginning 13 April 2020 (Fig. 1a). A decrease of 28.7%
was seen in the period 2 March to 19 April 2020, by comparison
to average weekly attendance in the 6-week period, 20 January
to 1 March. Subsequently, a recovery from this point is observed
with patient attendances returning towards pre-COVID levels by
the week beginning 20 July at −7.5% by comparison to average
weekly attendance in the 6-week period, 20 January to 1st
March (Fig. 1a). Compared to 2019, attendance in April 2020
decreased by 17.2%, and in June 2020 by 3.1% (p ≤ 0.001)
(Fig. 1a).
Our national data also enable us to explore regional variation
between the three cancer networks (Fig. 1c). Interestingly, a
similar fall in patient attendances was seen in SCAN and in NCA,
but a greater and more rapid decrease in WoSCAN. The rate of
recovery in all regions appears similar with a nadir in the week
beginning 13 April (SCAN −21.9%, NCA −20.3% and WOSCAN
−36.3%; SCAN versus NCA, p= 0.813, SCAN versus WOSCAN, p=
−0.002, NCA versus WOSCAN, p < 0.001), before subsequent
recovery.
On assessment of the impact of route, IV, subcutaneous (SC)
and PO administration of SACT were all reduced (Fig. 1b). The
nadir was observed for all routes of administration in the week
beginning 13 April and the decrease was predominantly
observed for IV SACT (−34.8%), but a proportionally similar
decrease was observed for SC SACT (−30.9%, IV versus SC, p=
0.465), and a smaller decrease for PO SACT(−11.24%, PO versus
IV, p < 0.001, and PO versus SC, p= 0.034). (Fig. 1b). This pattern is
the same for all regional networks.
The decrease in SACT varied according to tumour type (Fig. 1e).
The largest fall in weekly SACT treatment episodes was seen for
colorectal cancer (nadir at −43.4% for 6–12 April) and the smallest
for breast cancer (nadir at −19.7% for 20–26 April). A rapid
recovery in breast cancer SACT was observed (Fig. 1e), with an
increase of 17.7% in treatment episodes for the 4-week period 22
June to 19 July, compared to the 4-week period 16 March–12 April
(p= 0.009). In contrast, for colorectal and haematological cancers,
no significant change in SACT treatment episodes was observed
(−1.8%, p= 0.129 for colorectal cancer, and +4.0%, p= 0.452 for
haematological cancer), and, for lung cancer, a significant
decrease was observed (−13.2%, p= 0.038).
DISCUSSION
In this report, we demonstrate the impact of COVID-19 on SACT
delivery in Scotland. The initial decrease observed reflects the
uncertainty of the risks associated with SACT at the beginning of
the pandemic. This timing pre-dates the UK lockdown indicating
an awareness of early, small cohort data from other countries.
The subsequent rapid recovery reflects Scottish government
interim governance arrangements for cancer medicines that
enabled evidence-based, coordinated and transparent quick
adaptions to practice based on clinical consensus, and the
creation of COVID-19- protected SACT delivery in Scottish cancer
centres. Subsequently, larger observational studies, including
UKCCMP, provided weekly distribution of real-time data to UK
investigators and provided reassurance that SACT should be
offered to patients if possible. This generated confidence to
sustain the recovery of SACT delivery in NHS Scotland. Overall,
these actions, as our data show, have been important in limiting
the disadvantage to cancer patients.
A differing impact on SACT delivery was observed at a
regional level, with a greater initial decrease seen in WoSCAN.
This may reflect the highest incidence of COVID-19 in Scotland
being observed in two of the four health boards (NHS Greater
Glasgow and Clyde and NHS Lanarkshire) that together
comprise 73% of the WoSCAN population. Despite differences
in the extent and rate of decrease between regions, the rate of
recovery in all regions appears similar. A key reason for this is
likely to be the coordinated national recovery approach.
The lesser impact seen on PO SACT may be explained by the
drug’s mechanism of action and less need for hospital attendance,
which may have encouraged clinicians and patients to continue
treatment.
The impact on SACT delivery also varied by tumour site. Greater
initial decreases in treatment episodes were observed for color-
ectal, lung and haematological cancers compared to breast
cancer, and the subsequent recovery has been more rapid for
breast cancer. The reasons for this may include the different
impact on diagnostic modalities or perceived greater risk from
COVID-19 in different tumour types. A recent UK-wide analysis,
including Scottish centres, demonstrated a reduction in endo-
scopy, the main modality for diagnosing colorectal cancer to only
5% pre-COVID levels early in the pandemic with a recovery to only
20% 10 weeks later.11
The high quality and granularity of NHS Scotland cancer data
are enabling further research to allow a deeper understanding
of the impact of SACT in different tumour types. This includes
when sufficient follow-up has occurred, reporting short- and
longer-term outcomes such as cancer-specific survival, and
investigating the impact of other factors, for example, any
changes in stage at diagnosis due to delayed presentation to
healthcare services on outcomes. This analysis will allow
ongoing detailed and rapid investigation of the impact of
COVID-19 and associated response and recovery of cancer
pathway modifications.
A resurgence of SARS-CoV-2 infection has been observed as
lockdown restrictions are lifted. The ability to learn from
experience will form a key part of future strategies aimed at
avoiding any subsequent decrease in patient attendance for SACT
if a COVID-19 resurgence occurs. It is evident that not all regions of
the United Kingdom have been affected equally in terms of
COVID-19 incidence.12 Similarly, the impact of SACT delivery may
differ according to the administration route. The impact of COVID-
19 upon cancer referrals, diagnostic services, and other treatment
modalities will also impact SACT delivery, and may disproportion-
ally affect some tumour types. This is the subject of ongoing
analysis to ensure the observed recovery in SACT in NHS Scotland
is sustained.
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Fig. 1 Systemic Anti-Cancer Treatment (SACT) Delivery in Scotland during the COVID-19 Pandemic. a Weekly number of patient
attendances for systemic anticancer treatment (SACT) in NHS Scotland between the week beginning (wb) 20 January 2020 and the wb 20 July
2020. b Weekly SACT treatment episodes in NHS Scotland by route of administration, intravenous (IV), subcutaneous (SC) or oral. c Percent
change in weekly patient attendances for SACT by regional cancer networks. Percentage change calculated relative to a baseline value
determined by the average number of national patient attendances in the 6-week prior to the week beginning 2 March 2020. South of
Scotland Cancer Network (SCAN), West of Scotland Cancer Network (WoSCAN) and North of Scotland Cancer Alliance (NCA). d Percent change
in monthly SACT patient attendance for April 2019 versus April 2020, and June 2019 versus June 2020, by regional cancer networks and in
NHS Scotland. e Percent change in weekly SACT treatment episodes by tumour type. Percentage change calculated relative to a baseline value
determined by the average number of NHS Scotland treatment episodes in the 8 weeks prior to the week beginning 16 March 2020.
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